SCHEMBL19957201

SCHEMBL19957201

COc1cc2nccc(Oc3ccc([N+](=O)[O-])c(Cl)c3)c2cc1NC(C)=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 17/20 0.56
PDGFRA P16234 14/20 0.56
MET P08581 2/20 0.53
KIT P10721 4/20 0.51
RET P07949 3/20 0.51
PDGFRB P09619 3/20 0.51
FGFR1 P11362 3/20 0.51
FLT1 P17948 3/20 0.51
FLT4 P35916 3/20 0.51
DDR2 Q16832 3/20 0.51
RIPK2 O43353 2/20 0.51
STK10 O94804 2/20 0.51
ABL1 P00519 2/20 0.51
BCR P11274 2/20 0.51
SLC6A3 Q01959 2/20 0.51
DDR1 Q08345 2/20 0.51
MAP4K2 Q12851 2/20 0.51
PTK6 Q13882 2/20 0.51
AURKB Q96GD4 2/20 0.51
RIPK3 Q9Y572 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25307750 0.86 PDGFRA (0.62) KDRPDGFRAPDGFRBFGFR2EGFR
SCHEMBL31616944 0.86 PDGFRA (0.62) KDRPDGFRAPDGFRBFGFR2EGFR
SCHEMBL28429528 0.86 KDR (0.50) KDRPDGFRAMETKITRET
SCHEMBL19957375 0.85 KDR (0.53) KDRPDGFRAMETKITRET
SCHEMBL19957224 0.85 MET (0.57) KDRPDGFRAMETKITRET
SCHEMBL22505600 0.84 KDR (0.62) KDRPDGFRAMETKITRET
SCHEMBL19957087 0.84 KDR (0.52) KDRPDGFRAMETKITRET
SCHEMBL30433935 0.83 KDR (0.61) KDRPDGFRAMETKITRET
SCHEMBL19957006 0.83 KDR (0.61) KDRPDGFRAMETKITRET
SCHEMBL22505671 0.81 KDR (0.59) KDRPDGFRAMETKITRET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10654808-B2 Tyrosine kinase inhibitor and pharmaceutical composition comprising same Guangdong Raynovent Biotech Co., Ltd. (CN) 2020-05-19 US disclosed
US-20190119217-A1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Guangdong Raynovent Biotech Co., Ltd. (CN) 2019-04-25 US disclosed
EP-3293177-A1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2018-03-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190119217-A1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME ABL1, LCK, ERBB2 KDR 150/4885PDGFRA 127/4885MET 159/4885
US-10654808-B2 Tyrosine kinase inhibitor and pharmaceutical composition comprising same ABL1, LCK, ERBB2 KDR 150/4885PDGFRA 127/4885MET 159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.